文献速递浆细胞疾病

RARγ激动剂通过OAS-RNase L天然免疫通路增敏卡非佐米治疗多发性骨髓瘤

RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway.
PubMed 文献 · Blood · 2022-01-01

研究对1855种FDA已批准药物进行高通量筛选,发现全反式维甲酸(ATRA)本身无抗骨髓瘤作用,但可增强多发性骨髓瘤(MM)细胞对卡非佐米(Cfz)的敏感性,并使Cfz耐药细胞重新敏感。ATRA激活RARγ和干扰素-β反应通路,上调IRF1,进而启动OAS1转录;OAS1与Cfz诱导的双链RNA结合合成2-5A,经RNase L降解RNA导致细胞死亡。选择性RARγ激动剂BMS961具类似效应,ATRA和BMS961在体内均显著增强Cfz疗效;患者基因表达谱分析显示RARγ与OAS1表达和PI治疗反应呈强正相关。

要点

  • ATRA本身无抗骨髓瘤作用,但可增敏Cfz并使耐药MM细胞重新敏感
  • RARγ激动剂BMS961同样增敏Cfz,体内显著增强Cfz疗效
  • RARγ与OAS1表达和患者PI治疗反应呈强正相关

核心结论

  • RARγ激动剂(ATRA、BMS961)可增敏MM细胞对Cfz的细胞毒性,并使Cfz耐药MM细胞重新敏感。
  • RARγ激活通过干扰素-β反应通路上调IRF1,进而启动OAS1转录,经OAS-RNase L通路导致RNA降解和细胞死亡。
  • RARγ与OAS1表达和患者PI治疗反应呈强正相关,提示RARγ激动剂有克服MM对Cfz耐药的潜力。

研究设计与样本

  • 对1855种FDA已批准药物进行高通量筛选,鉴定可增强MM细胞对Cfz敏感性的药物。
  • 体外使用MM细胞系及Cfz耐药MM细胞评估ATRA和BMS961的增敏与再敏化作用。
  • 体内在已建立的MM模型中评估ATRA和BMS961对Cfz疗效的影响。
  • 分析患者基因表达谱大数据库,评估RARγ与OAS1表达与PI治疗反应的相关性。

主要发现

  • ATRA本身无抗骨髓瘤作用,但可增强MM细胞对Cfz诱导的细胞毒性的敏感性,并使Cfz耐药MM细胞重新敏感。
  • ATRA激活RARγ和干扰素-β反应通路,上调IRF1表达,IRF1启动OAS1转录。
  • OAS1与Cfz诱导的双链RNA结合合成2-5A,导致RNase L介导的细胞RNA降解和细胞死亡。
  • 选择性RARγ激动剂BMS961同样可(重新)增敏MM细胞对Cfz的敏感性。
  • ATRA和BMS961在体内均显著增强Cfz对已建立MM的治疗效果。

关键数值与推荐

  • 高通量筛选覆盖1855种FDA已批准药物。
  • 患者基因表达谱分析显示RARγ与OAS1表达和患者对PI治疗的反应呈强正相关。

临床怎么用

  • RARγ激动剂(如ATRA、BMS961)可能作为增敏剂与Cfz联合用于MM治疗。
  • RARγ与OAS1表达水平可能有助于预测患者对PI治疗的反应。
  • 该策略有望克服MM对PI治疗的获得性耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Proteasome inhibitors (PIs) such as bortezomib (Btz) and carfilzomib (Cfz) are highly efficacious for patients with multiple myeloma (MM). However, relapses are frequent, and acquired resistance to PI treatment emerges in most patients. Here, we performed a high-throughput screen of 1855 Food and Drug Administration (FDA)-approved drugs and identified all-trans retinoic acid (ATRA), which alone has no antimyeloma effect, as a potent drug that enhanced MM sensitivity to Cfz-induced cytotoxicity and resensitized Cfz-resistant MM cells to Cfz in vitro. ATRA activated retinoic acid receptor (RAR)γ and interferon-β response pathway, leading to upregulated expression of IRF1. IRF1 in turn initiated the transcription of OAS1, which synthesized 2-5A upon binding to double-stranded RNA (dsRNA) induced by Cfz and resulted in cellular RNA degradation by RNase L and cell death. Similar to ATRA, BMS961, a selective RARγ agonist, could also (re)sensitize MM cells to Cfz in vitro, and both ATRA and BMS961 significantly enhanced the therapeutic effects of Cfz in established MM in vivo. In support of these findings, analyses of large datasets of patients' gene profiling showed a strong and positive correlation between RARγ and OAS1 expression and patient's response to PI treatment. Thus, this study highlights the potential for RARγ agonists to sensitize and overcome MM resistance to Cfz treatment in patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wang Q, Lin Z, Wang Z, et al. RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood. 2022. PMID: 34411225. doi:10.1182/blood.2020009856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。